|
Recommended Pre-Conference Short Courses:* 9:00 am – 12:00 pm OR (SC5) Targeting Cancer Stem Cells with Biologics 2:00 – 5:00 *Separate Registration Required. PLENARY KEYNOTE SESSION
John F. Crowley, Founder, Novazyme Pharmaceuticals, Inc.
Paul J.H. Schoemaker, Ph.D., M.B.A., Chairman and Chief Executive Officer, Decision Strategies International, Inc.; Research Director, Mack Center for Technological Innovation; Adjunct Professor of Marketing, The Wharton School; Adjunct Professor, Wharton School of Business
DELIVERY: Tumor Penetration, Distribution and Beyond Introduction and Welcome–Delivery of Cancer Biologics Tugrul Kararli, Ph.D., President & Founder, Pharmacircle PENETRATION AND DISTRIBUTION Tumor Penetration of Therapeutic Antibodies-The Impact of Size and Exposure Time on Distribution David Blakey, Ph.D., Chief Scientist, Cancer and Infection Research Area, AstraZeneca Anti-Tumor Efficacy Maximization through Blocking Multiple Targets of Angiogenesis Dana Hu-Lowe, Ph.D., Group Leader, Associate Research Fellow, Cancer Biology, Pfizer, Inc. Optimizing Targeting of Anti-tumor Antibodies Gregory P. Adams, Ph.D., Co-Leader, Molecular and Translational Medicine Program, Fox Chase Cancer Center SELECTIVE TARGETING OF TUMORS Bispecific Antibodies: An Approach to Enhance Targeting Selectivity and Efficacy Matthew K. Robinson, Ph.D., Assistant Professor, Molecular and Translational Medicine Program, Fox Chase Cancer Center Selective Penetration and Targeting of Tumors Tapas K. Das Gupta, M.D., Ph.D., D.Sc., Professor and Head, Surgical Oncology, University of Illinois Chicago; Co-founder, CDG Therapeutics, Inc. A Systems Biology Approach to Engineering Therapeutic Antibodies: Development of an ErbB2/ErbB3 Bispecific Antibody Alexandra Huhalov, Ph.D., Principal Scientist, Merrimack Pharmaceuticals ENGINEERING FOR DELIVERY Tumor Targeting Theory-Kinetic & Diffusive Processes that Determine Antibody Macro & Microdistribution K. Dane Wittrup, Ph.D., C.P. Dubbs Professor, Chemical Engineering & Biological Engineering, Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology Nanoparticle Agents for Tumor Targeting and Penetration Shuming Nie, Ph.D., Wallace H. Coulter Distinguished Faculty Chair in Biomedical Engineering, Director, Emory-Georgia Tech Cancer Nanotechnology Center, Professor, BME Chemistry, Materials Science and Engineering and Hematology and Oncology, Emory University and Georgia Institute of Technology Antibody Mediated Cytoxicity Speakers to be Announced
Novel Modes Of Action For Cancer Biotherapeutics BI- AND TRI-SPECIFIC ANTIBODIES Mode of BiTE Antibody Action in Cancer Therapy Patrick Baeuerle, Ph.D., Chief Scientific Officer and Senior Vice President, Research & Development, Micromet, AG Catumaxomab (Removab), the First EC-approved Trifunctional Antibody: The Road from Pre-clinical Development to Approval and Beyond Diane Seimetz, Ph.D., M.D.R.A., Chief Scientific Officer & Executive Vice President, Fresenius Biotech GmbH Bispecific EGFR-IGF1R Program Eric Furfine, Senior Vice President, Research & Pre-clinical Development, Adnexus Therapeutics, a Bristol-Myers Squibb R&D Company Talk Title to be Announced Changshou Gao, Ph.D., Principal Scientist, Antibody Discovery and Protein Engineering, MedImmune, Inc. ADVANCES IN ANTIBODY-DRUG CONJUGATES A CD70 Directed Antibody Drug-Conjugate Comprising a Novel Highly Potent Alkylating Agent Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex, Inc. Pre-clinical and Clinical Development of Calicheamicin Derivatives Conjugated to Monoclonal Antibodies Hans-Peter Gerber, Senior Director, Tumor Therapies, Wyeth Oncology Discovery Antibody-Maytansinoid Conjugates: Demonstrating Benefit in the Treatment of Solid and Liquid Tumors John M. Lambert, Ph.D., Executive Vice President and Chief Scientific Officer, ImmunoGen, Inc. EFFECTOR-ENHANCED BIOTHERAPEUTICS Glycoengineering for the Enhancement of Antibody Activity Dennis Benjamin, Senior Director, Antibody Technologies, Seattle Genetics, Inc. Antibody Fc Engineering to Enhance Cytotoxicity, Pharmacokinetics, and Pharmacodynamics John R. Desjarlais, Vice President, Research, Xencor, Inc. Human RNase Fusion Proteins for Tumor Therapy Stefan Dübel Ph.D., Director, Biotechnology, Biochemistry and Biotechnology Institute, Technical University of Braunschweig NOVEL TARGETS AND APPROACHES Talk Title to be Announced René Hoet, Senior Director, Research, Genmab B.V. Talk Title to be Announced: Gary Woodnutt, CovX, a Pfizer Organization |
When Drug Research is Personal
Chips, Clones and Living Beyond 100
|
|
 |